Specialized Financing (Life Companies) Regulations

Marginal note:Limit of 25% of regulatory capital — investment in a specialized financing entity

• 7 (1) A life company shall not, by way of specialized financing activities, acquire control of, or hold, acquire or increase a substantial investment in, an entity controlled by a specialized financing entity of the life company or an entity in which the specialized financing entity of the life company holds a substantial investment, if the sum of the following exceeds or would exceed 25% of the life company’s regulatory capital:

  • (a) the aggregate balance sheet value of the shares and ownership interests held by the life company and its subsidiaries, whether individually or jointly, in the specialized financing entity of the life company, in the entities controlled by the specialized financing entity of the life company and in the entities in which that specialized financing entity holds a substantial investment, and

  • (b) the aggregate value of outstanding loans that the life company and its subsidiaries, whether individually or jointly, have made to the specialized financing entity of the life company, to the entities controlled by the specialized financing entity of the life company and to the entities in which that specialized financing entity holds a substantial investment.

• Marginal note:Limit of 25% of regulatory capital — investment in an entity

  (2) A life company shall not, by way of specialized financing activities, acquire control of, or hold, acquire or increase a substantial investment in, an entity, other than by way of an investment of a specialized financing entity controlled by the life company, if the sum of the following exceeds 25% of the life company’s regulatory capital:

  • (a) the aggregate balance sheet value of the shares and ownership interests that the life company and its subsidiaries, whether individually or jointly, would acquire in the entity,

  • (b) the aggregate balance sheet value of the shares and ownership interests held by the life company and its subsidiaries, whether individually or jointly, in the entities controlled by the life company by way of specialized financing activities and in the entities in which the life company holds a substantial investment by way of specialized financing activities, other than entities that the life company has acquired control of, or a substantial investment in, by way of an investment of a specialized financing entity of the life company, and

  • (c) the aggregate value of outstanding loans that the life company and its subsidiaries, whether individually or jointly, have made to the entities controlled by the life company by way of specialized financing activities and to the entities in which the life company holds a substantial investment by way of specialized financing activities, other than entities that the life company has acquired control of, or a substantial investment in, by way of an investment of a specialized financing entity of the life company.